Wang Bing, Cheng Li-Jing, Gao Zheng-Nan, Zhang Xiao-Yan, Huo Ming, Zhang Dong-Juan, Wu Jing, Wei Ming-Fen
Second Affiliated Hospital, Dalian Medical University , Dalian 116027, China.
Zhonghua Yi Xue Za Zhi. 2008 Mar 25;88(12):848-52.
To investigate the effects of liver X receptor (LXR) on the expression of fatty acid synthase (FAS) in diabetic liver.
Sixteen-week-old male db/db mice with C57BL/6 background were administered via gavaging of T0901317 (TO), a LXR synthetic agonist, at the dose of 3 mg x kg(-1) x d(-1) or dimethyl sulfide (DMSO), a vehicle alone for 7 days. Then the mice were killed with their livers taken out to undergo immunohistochemistry to observe the distribution of FAS protein. Human hepatocellular liver carcinoma cell of the line HepG2 were cultured with TO (10 micromol/L) or DMSO for 24 hours. Another HepG2 cells were transfected with mouse FAS promoter-luciferase reporter recombinants with or without pcDNA3.1, LXR expression vector, or an active sterol regulatory element binding protein-1c (SREBP-1c) expression vector for 12 hours. Real-time PCR and Western blotting were used to detect the levels of mRNA and protein of FAS and SREBP-1c respectively. Luciferase reporter assay was utilized to examine the activity of mouse FAS promoter.
FAS was abundantly expressed in the mouse livers, especially in the cytoplasm of liver cells. The FAS mRNA levels of the livers of the db/db mice was about 5.5 times as high as that of the db/m mice (P < 0.01). The FAS protein levels in the livers of db/db and db/m mice treated with TO were 1.7 and 3.5 times higher than those of the control mice (both P < 0.05). The SREBP-1 mRNA levels in the liver of the db/m and db/db mice treated with TO were 2.4 and 2.1 times higher compared with the control mice (P < 0.05, P < 0.01). Luciferase test showed that the FAS promoter activity of the HepG2 cells treated with TO was 1.5 times that of the control cells (P < 0.01). The FAS promoter activities of the HepG2 cells transfected with LXR and SREBP-1c were 1.9 and 1.6 times those of the control cells (botn P < 0.01).
LXRE directly or indirect (via SREBP-lc) upregulates the expression of FAS gene in the diabetic liver. LXR may mediate the lipid accumulation in liver of diabetes.
研究肝脏X受体(LXR)对糖尿病肝脏中脂肪酸合酶(FAS)表达的影响。
将16周龄具有C57BL/6背景的雄性db/db小鼠,通过灌胃给予LXR合成激动剂T0901317(TO),剂量为3 mg·kg⁻¹·d⁻¹,或单独给予溶剂二甲基亚砜(DMSO),持续7天。然后处死小鼠,取出肝脏进行免疫组织化学,观察FAS蛋白的分布。将人肝癌细胞系HepG2用TO(10 μmol/L)或DMSO培养24小时。另一些HepG2细胞用小鼠FAS启动子-荧光素酶报告基因重组体转染,同时转染或不转染pcDNA3.1、LXR表达载体或活性固醇调节元件结合蛋白-1c(SREBP-1c)表达载体,持续12小时。分别用实时PCR和蛋白质免疫印迹法检测FAS和SREBP-1c的mRNA和蛋白质水平。利用荧光素酶报告基因检测法检测小鼠FAS启动子的活性。
FAS在小鼠肝脏中大量表达,尤其在肝细胞的细胞质中。db/db小鼠肝脏的FAS mRNA水平约为db/m小鼠的5.5倍(P<0.01)。用TO处理的db/db和db/m小鼠肝脏中的FAS蛋白水平分别比对照小鼠高1.7倍和3.5倍(均P<0.05)。用TO处理的db/m和db/db小鼠肝脏中SREBP-1 mRNA水平分别比对照小鼠高2.4倍和2.1倍(P<0.05,P<0.01)。荧光素酶检测显示,用TO处理的HepG2细胞的FAS启动子活性是对照细胞的1.5倍(P<0.01)。转染LXR和SREBP-1c的HepG2细胞的FAS启动子活性分别是对照细胞的1.9倍和1.6倍(均P<0.01)。
LXR直接或间接(通过SREBP-1c)上调糖尿病肝脏中FAS基因的表达。LXR可能介导糖尿病肝脏中的脂质蓄积。